Collaboration - March 22, 2023
The state of Danish research examined in a new report
In the report “The scientific impact of Danish research 1980-2020,” the researchers behind the study state that the scientific impact of Danish research has been on the decline for a number of years. The report was commissioned and funded by the Novo Nordisk Foundation and VILLUM FONDEN and is an update of the report “Fostering […]
Collaboration - March 15, 2023
A leading Norwegian oncology arena
Cancer Crosslinks 2023 was a day of inspiration, insights, and interactions for professionals from across the cancer field in Norway and beyond. The 15th Cancer Crosslinks was held in Oslo Cancer Cluster Innovation Park on 26 January 2023, gathering the oncology community for a day of engaging talks from renowned international and Norwegian experts. The […]
Careers - March 13, 2023
Q&A: Jessica Martinsson, Director General, SwedenBIO
Jessica Martinsson took up her new role as Director General of SwedenBIO on March 1st 2023. NLS asked Jessica about her previous experiences from the life science industry and about current challenges and opportunities for Swedish life science companies. You are the co-founder of, and you have been both operational manager and CEO of Sprint […]
Agreement - February 23, 2023
AstraZeneca enters license agreement with KYM Biosciences
The companies have entered into a global exclusive license agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancer. Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialisation of CMG901 globally. CMG901 CMG901 is currently being evaluated in a […]
Agreement - January 17, 2023
Bristol Myers Squibb and Karolinska University Hospital enter collaboration
Karolinska University Hospital’s cancer department has signed an agreement with Bristol Myers Squibb to start an oncology and hematology research collaboration focusing on advancing research and generating data with an aim to deliver innovative therapies for patients. The organizations will centralize the work through a steering committee consisting of experts from both organizations to discuss […]
Agreement - January 10, 2023
CombiGene and Zyneyro enter collaboration agreement
The two companies have entered into a collaboration agreement regarding the continued development of Zyneyro’s peptide- and AAV-based treatment of chronic pain conditions. The agreement with Zyneyro is a cooperation agreement that means that Zyneyro and CombiGene share the project’s costs and revenues equally. “The concept of being able to give the pain-relieving peptide directly […]
